Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fecal Microbiota Transplantation (University Hospital, Clermont-Ferrand)
- Development stage
- Unknown
- Lead developer
- Centre Hospitalier Universitaire de Clermont-Ferrand
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Rectal
01
Overview
Fecal Microbiota Transplantation (FMT) is a microbiome-based therapeutic approach being developed by the University Hospital, Clermont-Ferrand, specifically for the prevention of Graft-versus-Host Disease (GvHD) in adult patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). The treatment involves the administration of a suspension containing 50g of processed donor stools via enema. The mechanism of action centers on the restoration of intestinal microbial diversity, which is typically depleted by pre-transplant conditioning and antibiotic use. By re-establishing a healthy microbiome, FMT aims to modulate the recipient's immune response, reduce systemic inflammation, and prevent the donor T-cell-mediated attack on host tissues that characterizes GvHD. This Phase II study evaluates FMT efficacy when administered shortly after neutrophil recovery.
- Other names
- FMTFaecal Microbiota TransplantationFecal Microbiota Transplant
Beyond the preview
Go deeper on Fecal Microbiota Transplantation (University Hospital, Clermont-Ferrand).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fecal Microbiota Transplantation (University Hospital, Clermont-Ferrand).